Visual hallucinations treated with the reinitiation of memantine in a patient with Lewy body dementia

Monica L Mathys1, Jamie McCarrell, Rebecca B Sleeper

  • 1School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX, USA. monica.mathys@ttuhsc.edu

Abstract

Insights

Discontinuing memantine in a patient with dementia with Lewy bodies (DLB) led to worsening hallucinations and cognitive decline. Reintroducing memantine rapidly improved these symptoms, highlighting its potential role in managing DLB psychiatric symptoms.

Area of Science:

  • Neurology
  • Psychiatry
  • Pharmacology

Background:

  • Dementia with Lewy bodies (DLB) is a progressive neurodegenerative disorder.
  • Psychiatric symptoms, including hallucinations, are common in DLB.
  • Memantine is an NMDA receptor antagonist used in Alzheimer's disease, with limited investigation in DLB.

Observation:

  • A 78-year-old man with DLB experienced stable cognitive and functional status on donepezil and memantine.
  • Upon memantine withdrawal due to institutional restrictions, the patient showed significant cognitive decline and severe visual hallucinations.
  • Reinitiation of memantine resulted in rapid resolution of hallucinations and improvement in cognition and function.

Findings:

  • Memantine withdrawal was associated with a marked exacerbation of psychiatric and cognitive symptoms in a DLB patient.
  • Reintroduction of memantine led to a significant and rapid improvement in hallucinations and overall status.
  • Existing literature, though limited, suggests memantine may benefit psychiatric symptoms in DLB.

Implications:

  • Memantine may play a crucial role in managing psychiatric symptoms, particularly hallucinations, in patients with DLB.
  • Abrupt discontinuation of memantine could precipitate severe symptom exacerbation in DLB patients.
  • Further research is warranted to establish the efficacy and optimal use of memantine for DLB management.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...